All Posts
Phase 2 RCT: Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer.
24 Apr, 2022 | 23:53h | UTC
Commentary on Twitter
In the phase II NEOBLADE trial in 120 pts with locally advanced MIBC, addition of the multitarget RTK TKI nindetanib to neoadjuvant chemotherapy did not significantly improve the pCR rate: 37% versus 32% (OR 1.25, 70% CI 0.84–1.87; P=0.28): https://t.co/m9NXouhOcZ #blcsm
— NatureRevClinOncol (@NatRevClinOncol) April 22, 2022
RCT: Pembrolizumab vs. chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
24 Apr, 2022 | 23:52h | UTCPembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study – The Lancet Oncology (link to abstract – $ for full-text)
CDC alerts providers to hepatitis cases of unknown origin.
22 Apr, 2022 | 09:34h | UTCCommentaries:
CDC issues health advisory about acute hepatitis in children – CNN
CDC Issues Alert for Hepatitis in Children With Adenovirus Infection – WebMD
Related:
Could Mysterious Hepatitis Cases be Triggered by COVID-19? – Health Policy Watch
U.S., U.K. investigating unusual cases of hepatitis in young children – STAT
Mysterious liver illness seen in kids in US, Europe – Associated Press
Policy stringency and mental health during the COVID-19 pandemic: a longitudinal analysis of data from 15 countries.
22 Apr, 2022 | 09:28h | UTC
UK drug regulator advises patients and doctors against the use of Pregabalin during pregnancy due to a possible increased risk of congenital malformations.
22 Apr, 2022 | 09:31h | UTCSee also: Pregabalin and risks in pregnancy – Medicines and Healthcare products Regulatory Agency
Source: Avoid prescribing pregabalin during pregnancy if possible, says UK drug regulator – The BMJ ($)
Commentary on Twitter
The Medicines and Healthcare Products Regulatory Agency (@MHRAgovuk) has strengthened its warning about avoiding pregabalin during pregnancy after new data showed an increased risk of major congenital malformations associated with the drug https://t.co/ghGvqCqA0C
— The BMJ (@bmj_latest) April 22, 2022
One-year follow-up of a RCT: In ICU patients with severe hypoxemia, there was no difference in long-term mortality and health-related quality of life with lower vs. higher oxygenation targets.
22 Apr, 2022 | 09:32h | UTCOriginal Study: Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure – New England Journal of Medicine
Commentary on Twitter
Lower (8 kPa) vs higher oxygenation (12 kPa) targets: no longterm survival benefit nor HRQoL improvement at 1y in #ICU pts with severe hypoxaemia (HOT-ICU trial cohort). Substantial impairments in several EQ-5D-5L dimensions in survivors in both groups.
🖇️ https://t.co/P48Cd5sIWK pic.twitter.com/JBFEIqDdcB— Intensive Care Medicine (@yourICM) April 20, 2022
M-A: Clinical efficacy of adjuvant treatments for patients with resected biliary tract cancer.
22 Apr, 2022 | 09:26h | UTC
Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art.
22 Apr, 2022 | 09:22h | UTC
State of the Art Review: Novel treatments in B cell non-Hodgkin’s lymphomas.
22 Apr, 2022 | 09:24h | UTCNovel treatments in B cell non-Hodgkin’s lymphomas – The BMJ
Commentary on Twitter
READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.
Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv
— The BMJ (@bmj_latest) April 22, 2022
PRISMA 2020 and PRISMA-S: common questions on tracking records and the flow diagram.
22 Apr, 2022 | 09:19h | UTC
RCT: Calorie restriction combined with time-restricted eating (eating from 8:00 am to 4:00 pm) did not significantly decrease weight loss compared to calorie restriction alone at 12 months (net difference, −1.8 kg; 95% CI, −4.0 to 0.4; P=0.11).
21 Apr, 2022 | 10:31h | UTCCalorie Restriction with or without Time-Restricted Eating in Weight Loss- New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Time-Restricted Eating No Better Than Cutting Calories for Obesity – HealthDay
Commentary on Twitter
As compared with calorie restriction, time-restricted eating does not produce additional benefits with regard to reduction of body weight, body fat, and metabolic risk factors. https://t.co/Ygx4zbC6QP pic.twitter.com/TGE5Pva3yS
— NEJM (@NEJM) April 20, 2022
Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.
22 Apr, 2022 | 09:21h | UTCInvited Commentary: Game-changing study of second-line HIV treatment – The Lancet HIV (free registration required)
Original Study: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine
Commentary on Twitter
Efficacy and safety of DTG or DRV in combination with 3TC + ZDV or TDF for second-line treatment of HIV infection (NADIA)… https://t.co/XajA2rLzsp DTG & DRV-based ART maintain good viral suppression during 96 wks; DTG non-inferior to DRV but ⬆️risk of resistance in 2rd-line Rx.
— Carlos del Rio (@CarlosdelRio7) April 21, 2022
RCT: Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of Covid-19.
21 Apr, 2022 | 10:29h | UTC
Commentary on Twitter
AZD7442 (tixagevimab/cilgavimab) found to have about 76% efficacy in preventing symptomatic Covid-19 infection. https://t.co/8tmvz3xI4I pic.twitter.com/fOegZjBRA6
— NEJM (@NEJM) April 20, 2022
[News release – not published yet] New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV.
21 Apr, 2022 | 10:28h | UTCRelated Study: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)
Cohort study: COVID-19 infection granted patients strong and long-lasting protection from reinfection.
21 Apr, 2022 | 10:20h | UTCNews Release: COVID-19 infection granted patients strong and long-lasting protection from reinfection – Providence Health & Services
Original Study: Rates of COVID-19 Among Unvaccinated Adults With Prior COVID-19 – JAMA Network Open
Commentary: COVID-19 infection may offer similar immunity as vaccination – CIDRAP
Commentary on Twitter
This US cohort study found that unvaccinated individuals with prior symptomatic #COVID19 had 85% lower risk against recurrent COVID-19 compared to unvaccinated individuals without prior infection, for up to 9 months, through November, 2021. https://t.co/1qHCFmGqXG
— JAMA Network Open (@JAMANetworkOpen) April 20, 2022
SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents.
21 Apr, 2022 | 10:23h | UTCEditorial: Communicating the Benefits of Vaccination in Light of Potential Risks
SCAI Position Statement on best practices for percutaneous axillary arterial access and training.
21 Apr, 2022 | 10:02h | UTCCommentary: Percutaneous Axillary Access: SCAI Calls for Best Practices – TCTMD
Commentary on Twitter
@SCAI releases new document on "Best Practices on Percutaneous Transaxillary Arterial Access and Training."https://t.co/TFsK84nFMe pic.twitter.com/7jNSeuSdEF
— MyJSCAI (@MyJSCAI) April 19, 2022
Vitamin D supplements in pregnancy: what’s the latest evidence?
21 Apr, 2022 | 09:58h | UTCVitamin D supplements in pregnancy: what’s the latest evidence? – Evidently Cochrane Blog
Original Study: Vitamin D supplementation for women during pregnancy – Cochrane Library
USPSTF Draft Statement: Postmenopausal women should not use hormone therapy to prevent chronic health problems.
20 Apr, 2022 | 10:15h | UTCDraft Recommendation Statement: Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons – U.S. Preventive Services Task Force
Commentary: USPSTF Advises Against Hormone Therapy to Prevent Chronic Conditions – HealthDay
British Guideline for the treatment of chronic lymphocytic leukemia.
21 Apr, 2022 | 10:00h | UTCGuideline for the treatment of chronic lymphocytic leukaemia – British Journal of Haematology
RCT: Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
21 Apr, 2022 | 09:56h | UTCIvosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Ivosidenib and azacitidine showed clinical benefit as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated AML, a difficult-to-treat population. https://t.co/6K6mWJdd2V pic.twitter.com/qOwOvHcV4j
— NEJM (@NEJM) April 20, 2022
Studies highlight meningitis vaccine’s potential against gonorrhea.
20 Apr, 2022 | 10:06h | UTCCommentary: Studies highlight meningitis vaccine’s potential against gonorrhea – CIDRAP
News Release: Threat of untreatable gonorrhoea could be tackled using an existing meningitis vaccine – The Lancet
Study 1: Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
Study 2: Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
An observational study suggests coprescription of Phosphodiesterase Type 5 Inhibitors (i.e., sildenafil) and oral Nitrates is not associated with increased risk of adverse cardiovascular outcomes in male patients with ischemic heart disease.
20 Apr, 2022 | 10:11h | UTCCommentaries:
PDE5 Inhibitors Prescribed for Men on Oral Nitrates for IHD – HealthDay
Retinal age gap as a predictive biomarker of future risk of Parkinson’s disease.
21 Apr, 2022 | 09:54h | UTCRetinal age gap as a predictive biomarker of future risk of Parkinson’s disease – Age and Ageing
Related: Retinal age gap as a predictive biomarker for mortality risk – British Journal of Ophthalmology (link to abstract – $ for full-text)
Big Tech in Healthcare: Here’s who wins and loses as Alphabet, Amazon, Apple, and Microsoft target niche sectors of healthcare.
20 Apr, 2022 | 09:59h | UTC